ConductScience.org, home

Paper25757

Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Brogden RN and 3 others. Drugs, 1978. Cited by 104 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Labetalol: a review of its pharmacology and therapeutic use in hypertension. Papers, record 25757. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25757

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Labetalol: a review of its pharmacology and therapeutic use in hypertension.
PubMed
Journal
Drugs
PubMed
Year
1978
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
104
iCite
Relative citation ratio, by iCite
7.56
iCite
Revised in PubMed
2026-10-11
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Brogden RNR N
2Heel RCR C
3Speight TMT M
4Avery GSG S

Source PubMed

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
EthanolaminesMajor topic
HypertensionMajor topic
LabetalolMajor topic
Adrenal Gland Neoplasms
Adrenergic alpha-Antagonists
Adrenergic beta-Antagonists
Angiotensin II
Half-Life
Hemodynamics
Humans
Pheochromocytoma
Renin
Respiration

Source PubMed

References58

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112,115Antihypertensive effect of labetalol, a new alpha- and beta-adrenergic blocking agent.Int J Clin Pharmacol Biopharm1976https://conductscience.org/library/papers/12115PubMed
210,948A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.Br J Clin Pharmacol1976https://conductscience.org/library/papers/10948PubMed
3791,330Experience with labetalol in hypertension.Br J Clin Pharmacol1976https://conductscience.org/library/papers/791330PubMed
4990,158Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.Br J Clin Pharmacol1976https://conductscience.org/library/papers/990158PubMed
5990,159Cardiovascular effects of labetalol during halothane anaesthesia.Br J Clin Pharmacol1976https://conductscience.org/library/papers/990159PubMed
6236,806Comparison of intravenous AH 5158 (ibidomide) and propranolol in asthma.Br Med J1975https://conductscience.org/library/papers/236806PubMed
7791,333Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.Br J Clin Pharmacol1976https://conductscience.org/library/papers/791333PubMed
862,582Labetalol in long-term treatment of hypertension.Br J Clin Pharmacol1976https://conductscience.org/library/papers/62582PubMed
9843,418Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise.Br J Clin Pharmacol1977https://conductscience.org/library/papers/843418PubMed
10791,332Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine.Br J Clin Pharmacol1976https://conductscience.org/library/papers/791332PubMed
11851,058Acute hemodynamic effects of an alpha- and beta-receptor blocking agent (AH 5158) on the systemic and pulmonary circulation at rest and during exercise in hypertensive patients.Am Heart J1977https://conductscience.org/library/papers/851058PubMed
1269,898Scalp tingling in patients on labetalol.Lancet1977https://conductscience.org/library/papers/69898PubMed
1314,627Labetalol (AH5158), a competitive alpha- and beta-receptor blocking drug, in the management of hypertension.Aust N Z J Med1976https://conductscience.org/library/papers/14627PubMed
144,184Proceedings: The effects of AH 5158 on the overflow of transmitter and the uptake of (3H)-(--)-noradrenaline in the cat spleen.Br J Pharmacol1976https://conductscience.org/library/papers/4184PubMed
154,152,254The effects of a new alpha- and beta-adrenoceptor antagonist (AH5158) upon the general and coronary haemodynamics of intact dogs.Br J Pharmacol1973https://conductscience.org/library/papers/4152254PubMed
164,404,413Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.Br J Pharmacol1972https://conductscience.org/library/papers/4404413PubMed
1710,953Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs.Br J Clin Pharmacol1976https://conductscience.org/library/papers/10953PubMed
18238,705Combined alpha- and beta-adrenoceptor blocking drug AH 5158: further studies on alpha-adrenoceptor blockade in anaesthetized animals.Br J Pharmacol1975https://conductscience.org/library/papers/238705PubMed
19901,712Rate of onset of hypotensive response with oral labetalol [proceedings].Br J Clin Pharmacol1977https://conductscience.org/library/papers/901712PubMed
2022,454,938The effects of oral AH 5158, a combined α and β-adrenoceptor antagonist, in healthy volunteers.Br J Clin Pharmacol1974https://conductscience.org/library/papers/22454938PubMed

See all 58 references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 104 citations.

PMIDTitleJournalYearIn PapersSource
36,365,181Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations.Pharmaceutics2022https://conductscience.org/library/papers/36365181PubMed
7,426,837Direct vasodilatation by labetalol in anaesthetized dogs.Br J Pharmacol1980https://conductscience.org/library/papers/7426837PubMed
7,374,093Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension.Klin Wochenschr1980https://conductscience.org/library/papers/7374093PubMed
7,295,465Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension.Br J Clin Pharmacol1981https://conductscience.org/library/papers/7295465PubMed
7,180,007The management of the patient with catecholamine excess.World J Surg1982https://conductscience.org/library/papers/7180007PubMed
7,093,098Labetalol: the nineteen-eighties.Br J Clin Pharmacol1982https://conductscience.org/library/papers/7093098PubMed
6,980,012Review of long-term treatment with labetalol.Br J Clin Pharmacol1982https://conductscience.org/library/papers/6980012PubMed
6,310,204Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension.Klin Wochenschr1983https://conductscience.org/library/papers/6310204PubMed
6,151,890Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.Drugs1984https://conductscience.org/library/papers/6151890PubMed
6,124,264Labetalol in essential hypertension.Br J Clin Pharmacol1982https://conductscience.org/library/papers/6124264PubMed
6,122,340Improved deep controlled hypotension in aneurysmal surgery.Acta Neurochir (Wien)1982https://conductscience.org/library/papers/6122340PubMed
6,103,797Antinuclear antibodies and cardiovascular drugs.Drugs1980https://conductscience.org/library/papers/6103797PubMed
3,154,919Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.Cardiovasc Drugs Ther1988https://conductscience.org/library/papers/3154919PubMed
2,908,732Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.Cardiovasc Drugs Ther1988https://conductscience.org/library/papers/2908732PubMed
2,872,908Effect of labetalol on limb haemodynamics in patients following coronary artery bypass graft surgery.Br J Clin Pharmacol1986https://conductscience.org/library/papers/2872908PubMed
2,770,185[Effectiveness and hemodynamic mechanism of action of blood pressure lowering by intravenous labetalol in patients with a critical increase in blood pressure].Klin Wochenschr1989https://conductscience.org/library/papers/2770185PubMed
2,663,413Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.Drugs1989https://conductscience.org/library/papers/2663413PubMed
1,678,963
Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.
Cardiovasc Drugs Ther1991https://conductscience.org/library/papers/1678963PubMed
732,886Release of noradrenaline by labetalol in the rat anococcygeus muscle.Naunyn Schmiedebergs Arch Pharmacol1978https://conductscience.org/library/papers/732886PubMed
583,322Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin.Br J Clin Pharmacol1979https://conductscience.org/library/papers/583322PubMed

See all 26 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25757

GET https://conductscience.org/api/papers/v1/25757/references?page=2